Chandler says that plucking out a few of the beads would not be cost-effective, although perhaps a few dozen biomarkers might be enough to catch the most common afflictions and permit a less expensive assessment. He would like data from 10,000 clients before pruning the number of biomarkers. (He expects about 1,500 customers by the end of 2007.) The company may head in the other direction and institute a Biophysical300 as research uncovers more biomarkers. I’d certainly be game for it if the price came down—and as long as it does not need more than two tablespoons of blood.